Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis
JNCI Cancer Spectrum · 2024
DOI: 10.1093/jncics/pkae091 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Hanano Ando und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: B7-2 Antigen, Papillomavirus Vaccines, Uterine Cervical Neoplasms, Uterine Cervical Dysplasia. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GLOVACC, Japan AMED.
Abstract (Originalsprache)
Background
Although therapeutic human papillomavirus vaccines could offer a noninvasive treatment for patients with cervical intraepithelial neoplasia, none has been clinically implemented. Oral administration of the therapeutic human papillomavirus vaccine IGMKK16E7 results in the histological regression of human papillomavirus 16–positive cervical intraepithelial neoplasia 2/3 to normal (complete response). We investigated biomarkers that could predict complete response after oral administration of IGMKK16E7.
Methods
Forty-two patients administered high-dose oral IGMKK16E7 in a phase I/II trial were included. Cervix-exfoliated cells were collected before vaccine administration. Gene expression of CD4, CD8, FOXP3, programmed cell death 1 protein, CTLA4, CD103, CD28, CD80, CD86, and programmed cell death 1 ligand 1 in the cells was measured by quantitative reverse transcriptase–polymerase chain reaction. Receiver operating characteristic curve analysis and Mann-Whitney tests were used to explore potential biomarkers. Pearson correlation coefficient analysis was used to correlate gene expression profiles with clinical outcome.
Results
The only predictive biomarker of vaccine response for which receiver operating characteristic curve analysis showed significant diagnostic performance with histological complete response was CD86 (area under the curve = 0.71, 95% confidence interval = 0.53 to 0.88, P = .020). Patients with complete response had significantly lower CD86 expression (CD86-low) than patients with no complete response (P = .035). The complete response rates for CD86-low and CD86-high patients were 50% and 19%, respectively, and CD86-low patients had a significantly higher complete response rate (P = .047). Compared with all patients, the CD86-low group had a 1.5-fold increase in the complete response rate. Gene expression of CD86 and CTLA4 showed the strongest positive correlation with clinical outcomes in the incomplete response group (P < .001).
Conclusion
Low expression of CD86 in exfoliated cervical cells can be used as a pretreatment biomarker to predict histological complete response after IGMKK16E7 administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.
- Department of Functional Morphology, Nihon University School of Medicine, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
- Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences, Kanazawa University, Ishikawa, Japan.
ORCID-Profile: Daisuke Aoki, Kei Kawana
Förderung
- GLOVACC
- Japan AMED
Zitieren
APA
Ando, H., Katoh, Y., Kobayashi, O., Ikeda, Y., Yahata, H., Iwata, T., Satoh, T., Akiyama, A., Maeda, D., Hori-Hirose, Y., Uemura, Y., Nakayama-Hosoya, K., Katoh, K., Nakajima, T., Taguchi, A., Komatsu, A., Kamata, S., Tomita, N., Kato, K., …, & Kawana, K. (2024). Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae091
Vancouver
Ando H, Katoh Y, Kobayashi O, Ikeda Y, Yahata H, Iwata T, et al. Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae091
BibTeX
@article{Ando2024,
author = {Ando, Hanano and Katoh, Yuki and Kobayashi, Osamu and Ikeda, Yuji and Yahata, Hideaki and Iwata, Takashi and Satoh, Toyomi and Akiyama, Azusa and Maeda, Daichi and Hori-Hirose, Yumiko and Uemura, Yukari and Nakayama-Hosoya, Kaori and Katoh, Kanoko and Nakajima, Takahiro and Taguchi, Ayumi and Komatsu, Atsushi and Kamata, Saki and Tomita, Naoko and Kato, Kiyoko and Aoki, Daisuke and Igimi, Shizunobu and Kawana-Tachikawa, Ai and Schust, Danny J and Kawana, Kei},
title = {Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis},
journal = {JNCI Cancer Spectrum},
year = {2024},
doi = {10.1093/jncics/pkae091}
}
EUVIMED